Schwab Charles Investment Management Inc. Acquires 20,196 Shares of MacroGenics Inc (MGNX)

Schwab Charles Investment Management Inc. grew its holdings in MacroGenics Inc (NASDAQ:MGNX) by 13.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 168,988 shares of the biopharmaceutical company’s stock after acquiring an additional 20,196 shares during the period. Schwab Charles Investment Management Inc. owned about 0.46% of MacroGenics worth $3,123,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Wells Fargo & Company MN boosted its holdings in shares of MacroGenics by 11.5% in the 3rd quarter. Wells Fargo & Company MN now owns 27,714 shares of the biopharmaceutical company’s stock valued at $513,000 after acquiring an additional 2,862 shares during the last quarter. Citadel Advisors LLC boosted its holdings in shares of MacroGenics by 55.3% in the 3rd quarter. Citadel Advisors LLC now owns 85,927 shares of the biopharmaceutical company’s stock valued at $1,588,000 after acquiring an additional 30,594 shares during the last quarter. Sphera Funds Management LTD. boosted its holdings in shares of MacroGenics by 157.0% in the 3rd quarter. Sphera Funds Management LTD. now owns 208,700 shares of the biopharmaceutical company’s stock valued at $3,857,000 after acquiring an additional 127,500 shares during the last quarter. Hood River Capital Management LLC boosted its holdings in shares of MacroGenics by 2.2% in the 3rd quarter. Hood River Capital Management LLC now owns 588,799 shares of the biopharmaceutical company’s stock valued at $10,881,000 after acquiring an additional 12,606 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its holdings in shares of MacroGenics by 9.6% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 228,500 shares of the biopharmaceutical company’s stock valued at $3,745,000 after acquiring an additional 20,000 shares during the last quarter. 85.77% of the stock is currently owned by institutional investors and hedge funds.

MacroGenics Inc (MGNX) opened at $20.53 on Tuesday. MacroGenics Inc has a 12 month low of $14.36 and a 12 month high of $22.31. The stock has a market cap of $755.97, a price-to-earnings ratio of -4.56 and a beta of 2.73.

MacroGenics (NASDAQ:MGNX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.19). The firm had revenue of $1.70 million during the quarter, compared to analyst estimates of $5.50 million. MacroGenics had a negative net margin of 1,526.55% and a negative return on equity of 69.31%. The business’s revenue for the quarter was down 48.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.97) earnings per share. research analysts expect that MacroGenics Inc will post -0.7 EPS for the current year.

Several equities analysts recently issued reports on MGNX shares. Cowen reiterated a “buy” rating on shares of MacroGenics in a research note on Wednesday, October 25th. Zacks Investment Research cut shares of MacroGenics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. ValuEngine upgraded shares of MacroGenics from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st. Raymond James Financial reiterated a “buy” rating on shares of MacroGenics in a research note on Monday, December 11th. Finally, Citigroup boosted their target price on shares of MacroGenics from $18.00 to $22.00 and gave the company a “neutral” rating in a research note on Friday, November 10th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $30.10.

In other MacroGenics news, SVP Jon Marc Wigginton sold 5,000 shares of the company’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the completion of the transaction, the senior vice president now directly owns 35,000 shares in the company, valued at $700,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 8.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://weekherald.com/2018/01/16/schwab-charles-investment-management-inc-acquires-20196-shares-of-macrogenics-inc-mgnx.html.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply